Aurobindo Pharma Limited has completed the transfer of its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary. The transfer took effect from July 1, 2026, following the execution of a Business Transfer Agreement on April 6, 2026. The business is now being undertaken in Auropharm Limited as a going concern on a slump sale basis.
The Board of Directors approved the transfer through a unanimous decision, enabling the Company to streamline its operational structure and focus its resources strategically. The Business Transfer Agreement outlines clear terms governing the complete transfer of business assets, ensuring a seamless transition process.
Auropharm Limited will now assume responsibility for the transferred business, maintaining continuity in operations for domestic branded generic pharmaceutical formulations. The arrangement follows compliance with Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The completion of this transfer represents a strategic move by Aurobindo Pharma Limited to optimize its business portfolio. The subsidiary structure allows for better management of different business segments and enhanced focus on core strategic priorities. The transfer has been officially notified to both NSE and BSE for necessary record-keeping and compliance purposes.
This transfer marks a significant milestone in Aurobindo Pharma Limited's corporate restructuring efforts, enabling more focused growth in its core pharmaceutical manufacturing and distribution activities across domestic markets. The Company's Management has expressed confidence in the successful execution of this strategic business reorganization.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.